TNSN01028A1 - Derives de purine nouveaux, procede pour leur preparation et compositions les contenant - Google Patents

Derives de purine nouveaux, procede pour leur preparation et compositions les contenant

Info

Publication number
TNSN01028A1
TNSN01028A1 TNTNSN01028A TNSN01028A TNSN01028A1 TN SN01028 A1 TNSN01028 A1 TN SN01028A1 TN TNSN01028 A TNTNSN01028 A TN TNSN01028A TN SN01028 A TNSN01028 A TN SN01028A TN SN01028 A1 TNSN01028 A1 TN SN01028A1
Authority
TN
Tunisia
Prior art keywords
preparation
compositions containing
purine derivatives
novel purine
compounds
Prior art date
Application number
TNTNSN01028A
Other languages
English (en)
Inventor
John Mantell Simon
Marina Monaghan Sandra
Thomas Stephenson Peter
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN01028A1 publication Critical patent/TNSN01028A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)

Abstract

L’INVENTION CONCERNE LES COMPOSES DE FORMULE (I) : DANS LAQUELLE R1, R2, R7 ET R8 REPRESENTENT L’HYDROGENE OU DES RADICAUX ORGANIQUES, ET A REPRESENTE UNE LIAISON OU UN GROUPE ALKYLENE EN C1 A C6. ELLE CONCERNE EGALEMENT DES PROCEDES POUR LEUR PREPARATION, LES INTERMEDIAIRES UTILISES DANS LEUR PREPARATION, AINSI QUE DES COMPOSITIONS LES CONTENANT. APPLICATION : UTILISATION DE CES COMPOSES ET COMPOSITIONS COMME AGONISTES DES RECEPTEURS D'ADENOSINE A2A POUR LE TRAITEMENT DE DIVERSES MALADIES.
TNTNSN01028A 2000-02-18 2001-02-16 Derives de purine nouveaux, procede pour leur preparation et compositions les contenant TNSN01028A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0003960.2A GB0003960D0 (en) 2000-02-18 2000-02-18 Purine derivatives

Publications (1)

Publication Number Publication Date
TNSN01028A1 true TNSN01028A1 (fr) 2005-11-10

Family

ID=9886026

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN01028A TNSN01028A1 (fr) 2000-02-18 2001-02-16 Derives de purine nouveaux, procede pour leur preparation et compositions les contenant

Country Status (39)

Country Link
US (1) US6525032B2 (fr)
EP (1) EP1255764B8 (fr)
JP (1) JP2004508284A (fr)
KR (1) KR20030036138A (fr)
CN (1) CN1400975A (fr)
AP (1) AP2002002598A0 (fr)
AR (1) AR027437A1 (fr)
AT (1) ATE325807T1 (fr)
AU (1) AU2001230440A1 (fr)
BG (1) BG106906A (fr)
BR (1) BR0108408A (fr)
CA (1) CA2400619A1 (fr)
CO (1) CO5271668A1 (fr)
CR (1) CR6722A (fr)
CZ (1) CZ20022703A3 (fr)
DE (1) DE60119492T2 (fr)
EA (1) EA004987B1 (fr)
EE (1) EE200200452A (fr)
ES (1) ES2260199T3 (fr)
GB (1) GB0003960D0 (fr)
GT (1) GT200100027A (fr)
HN (1) HN2001000027A (fr)
HR (1) HRP20020676A2 (fr)
HU (1) HUP0301055A2 (fr)
IL (1) IL150543A0 (fr)
IS (1) IS6458A (fr)
MA (1) MA26873A1 (fr)
MX (1) MXPA02008068A (fr)
NO (1) NO20023894L (fr)
NZ (1) NZ519971A (fr)
OA (1) OA12177A (fr)
PA (1) PA8511801A1 (fr)
PE (1) PE20011122A1 (fr)
PL (1) PL357220A1 (fr)
SK (1) SK11692002A3 (fr)
SV (1) SV2002000317A (fr)
TN (1) TNSN01028A1 (fr)
WO (1) WO2001060835A1 (fr)
ZA (1) ZA200206526B (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
GB9913932D0 (en) * 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
US6753322B2 (en) * 2000-06-06 2004-06-22 Pfizer Inc 2-aminocarbonyl-9H-purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
AU2002362443B2 (en) * 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
GB0129273D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
GB0129270D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Pharmaceutical combination
GB0129397D0 (en) * 2001-12-07 2002-01-30 Pfizer Ltd Pharmaceutical combination
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EA011826B1 (ru) 2004-05-26 2009-06-30 Инотек Фармасьютикалз Корпорейшн Пуриновые производные в качестве агонистов аденозиновых арецепторов и способы их применения
WO2006028618A1 (fr) * 2004-08-02 2006-03-16 University Of Virginia Patent Foundation Analogues d'adenosine de propynyle 2-polycyclique presentant des groupes 5'-ribose modifies presentant une activite agoniste de a2a
NZ585697A (en) * 2004-08-02 2011-12-22 Univ Virginia Patent Found 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
WO2006023272A1 (fr) * 2004-08-02 2006-03-02 University Of Virginia Patent Foundation Analogues de 2-polycyclique propynyle adenosine presentant une activite agoniste de a2a
US7863253B2 (en) * 2004-09-20 2011-01-04 Inotek Pharmaceuticals Corporation Purine Derivatives and methods of use thereof
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP2532677A1 (fr) 2005-10-21 2012-12-12 Novartis AG Anticorps humains dirigés contre l'IL -13 et utilisations thérapeutiques
CA2627319A1 (fr) * 2005-11-30 2007-06-07 Prakash Jagtap Derives de purine et leurs procedes d'utilisation
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
WO2007092936A2 (fr) * 2006-02-08 2007-08-16 University Of Virginia Patent Foundation Procédé pour traiter des lésions gastriques
WO2007120972A2 (fr) 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Procede permettant de traiter l'anemie a hematies falciformes
GB0607951D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
PL2322525T3 (pl) 2006-04-21 2014-03-31 Novartis Ag Pochodne puryny do zastosowania jako agoniści receptora adenozyny A<sub>2A</sub>
GB0607950D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
EP1889846A1 (fr) 2006-07-13 2008-02-20 Novartis AG Dérivés de purine comme agonistes du recepteur A2a
EP1903044A1 (fr) 2006-09-14 2008-03-26 Novartis AG Derivés de l'adénosine en tant qu' agonistes du récepteur A2A
BRPI0717564A2 (pt) 2006-09-29 2013-10-22 Novartis Ag Pirazolopirimidinas como inibidores de pi3k lipídeo cinase
CA2667962A1 (fr) 2006-10-30 2008-05-08 Novartis Ag Composes heterocycliques en tant qu'agents anti-inflammatoires
JP2008285478A (ja) * 2007-04-16 2008-11-27 Santen Pharmaceut Co Ltd アデノシンａ２ａ受容体アゴニストを有効成分として含有する緑内障治療剤
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
UA104010C2 (en) * 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
ES2396023T3 (es) 2009-01-29 2013-02-18 Novartis Ag Bencimidazoles sustituidos para el tratamiento de astrocitomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
JP5819831B2 (ja) 2009-08-17 2015-11-24 インテリカイン， エルエルシー 複素環式化合物およびそれらの使用
WO2011020861A1 (fr) 2009-08-20 2011-02-24 Novartis Ag Composés d'oximes hétérocycliques
US8877732B2 (en) 2010-01-11 2014-11-04 Inotek Pharmaceuticals Corporation Combination, kit and method of reducing intraocular pressure
MX2012010724A (es) 2010-03-26 2012-11-12 Inotek Pharmaceuticals Corp Metodo para reducir la presion intraocular en seres humanos empleando n6-ciclopentiladenosina (cpa), derivados de cpa o profarmacos de los mismos.
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
WO2012116237A2 (fr) 2011-02-23 2012-08-30 Intellikine, Llc Composés hétérocycliques et leurs utilisations
US9102671B2 (en) 2011-02-25 2015-08-11 Novartis Ag Compounds and compositions as TRK inhibitors
JP5957526B2 (ja) 2011-09-15 2016-07-27 ノバルティス アーゲー チロシンキナーゼとしての６−置換３−（キノリン−６−イルチオ）−［１，２，４］トリアゾロ［４，３−ａ］ピラジン
EP2793893A4 (fr) 2011-11-23 2015-07-08 Intellikine Llc Régimes de traitement améliorés utilisant des inhibiteurs de mtor
DK2807178T3 (en) 2012-01-26 2017-09-04 Inotek Pharmaceuticals Corp Anhydrous polymorphs of (2R, 3S, 4R, 5R) -5- (6- (cyclopentylamino) -9H-purin-9-yl) -3,4-dihydroxytetrahydrofuran-2-yl) methyl nitrate and processes for their preparation
EP3964513A1 (fr) 2012-04-03 2022-03-09 Novartis AG Produits combinés comprenant des inhibiteurs de tyrosine kinase et leur utilisation
CN105246482A (zh) 2013-03-15 2016-01-13 因特利凯有限责任公司 激酶抑制剂的组合及其用途
SG11201506882YA (en) 2013-03-15 2015-09-29 Inotek Pharmaceuticals Corp Ophthalmic formulations
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (fr) 2014-07-25 2016-01-28 Novartis Ag Polythérapie
US10940150B2 (en) 2014-07-28 2021-03-09 Technische Universitaet Dresden Thymine derivatives and quinazoline-dione derivatives for the inhibition of HSP27
US10195208B2 (en) 2014-07-31 2019-02-05 Novartis Ag Combination therapy
TW202242853A (zh) * 2015-03-13 2022-11-01 瑞典商杜比國際公司 解碼具有增強頻譜帶複製元資料在至少一填充元素中的音訊位元流
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5140015A (en) * 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US5189027A (en) * 1990-11-30 1993-02-23 Yamasa Shoyu Kabushiki Kaisha 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases
IT1254915B (it) * 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
ES2264826T3 (es) * 1998-10-16 2007-01-16 Pfizer Inc. Derivados de adenina.
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
GB9924363D0 (en) 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives

Also Published As

Publication number Publication date
CZ20022703A3 (cs) 2003-09-17
WO2001060835A1 (fr) 2001-08-23
EA200200770A1 (ru) 2002-12-26
CN1400975A (zh) 2003-03-05
JP2004508284A (ja) 2004-03-18
AU2001230440A1 (en) 2001-08-27
ATE325807T1 (de) 2006-06-15
SV2002000317A (es) 2002-07-16
ZA200206526B (en) 2003-10-16
EP1255764B1 (fr) 2006-05-10
SK11692002A3 (sk) 2003-11-04
BG106906A (en) 2003-04-30
AP2002002598A0 (en) 2002-09-30
IS6458A (is) 2002-07-05
DE60119492D1 (de) 2006-06-14
NO20023894D0 (no) 2002-08-16
NO20023894L (no) 2002-10-01
HRP20020676A2 (en) 2004-12-31
MXPA02008068A (es) 2004-04-05
NZ519971A (en) 2004-04-30
EE200200452A (et) 2003-12-15
EP1255764A1 (fr) 2002-11-13
EA004987B1 (ru) 2004-10-28
PE20011122A1 (es) 2001-11-06
US20010020089A1 (en) 2001-09-06
HUP0301055A2 (hu) 2003-08-28
EP1255764B8 (fr) 2006-06-28
ES2260199T3 (es) 2006-11-01
MA26873A1 (fr) 2004-12-20
PL357220A1 (en) 2004-07-26
CO5271668A1 (es) 2003-04-30
DE60119492T2 (de) 2006-11-09
AR027437A1 (es) 2003-03-26
GT200100027A (es) 2001-12-19
CA2400619A1 (fr) 2001-08-23
PA8511801A1 (es) 2002-02-21
OA12177A (en) 2006-05-09
CR6722A (es) 2003-11-25
HN2001000027A (es) 2001-09-11
BR0108408A (pt) 2002-11-26
IL150543A0 (en) 2003-02-12
KR20030036138A (ko) 2003-05-09
US6525032B2 (en) 2003-02-25
GB0003960D0 (en) 2000-04-12
WO2001060835A8 (fr) 2001-11-29

Similar Documents

Publication Publication Date Title
TNSN01028A1 (fr) Derives de purine nouveaux, procede pour leur preparation et compositions les contenant
TNSN00203A1 (fr) Derives de purine nouveaux, procede pour leur preparation et des compositions les contenant
TNSN00202A1 (fr) Derives de n-[(purine - 2- yl) methyl]-sulfonamide nouveaux, procede pour leur preparation et compositions les contenant
TNSN01134A1 (fr) Derives de purine nouveaux, procede pour leur preparation et compositions les contenant.
TNSN01096A1 (fr) Derives de purines nouveaux, procede pour leur preparation et compositions les contenant
TNSN99106A1 (fr) Derives d&#39;isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN02012A1 (fr) Derives de pyrimidine nouveaux inhibiteurs de mmp, et compositions les contenant
MA24729A1 (fr) Macrolides nouveaux.
MA26718A1 (fr) Derives de quinoleine-2-one a substituant heteroaryle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26696A1 (fr) Derives de tetrahydrobenzazepine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00228A1 (fr) Derives de benzimidazole nouveaux, et compositions les contenant
TNSN00133A1 (fr) DERIVES DE PURINE, PROCEDES ET PRODUITS INTERMEDIAIRES POUR LEUR PREPARATION, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, ET LEUR UTILISATION COMME AGONISTES DU RECEPTEUR A2a DE L&#39;ADENOSINE
TNSN01102A1 (fr) Derives de pyrazole nouveaux, procede pour leur preparation et compositions les contenant.
MA27121A1 (fr) Derives 2-(purin-9-yl)-tetrahydrofuran-3,4-diol
TNSN02008A1 (fr) Derives d&#39;acides isophtalique nouveaux inhibiteurs de mmp, et compositions les contenant
TNSN98194A1 (fr) Derives nouveaux de 6-o-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26723A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99170A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN01077A1 (fr) Derives de tropane nouveaux, procede pour leur preparation et compositions les contenant
MA29692B1 (fr) Derives de la xanthine en tant qu&#39;agonistes selectifs du hm74a
TNSN00065A1 (fr) Derives nouveaux de pyrimidine inhibiteurs de sorbitol- deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant.
TNSN98082A1 (fr) DERIVES SUBSTITUES EN C - 4 DE 9 - DESOXO - 9a - aza - 9a HOMOERYTHROMYCINE A.
TNSN02014A1 (fr) Composes nouveaux agonistes de ppar et compositions les contenant
TNSN99156A1 (fr) Derives d&#39;acide hydroxypipecolate-hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN02032A1 (fr) Derives de glutaramide a substituant n-phenpropylcyclopentyle nouveaux, et compositions les contenant.